Syndax Pharmaceuticals Inc Earnings Per Share Disclosure
6. Loss per Share
Basic and diluted loss per share are calculated as follows (in 000s except share data):
|
|
Years Ended December 31, |
|
|||||||||
|
|
2025 |
|
|
2024 |
|
|
2023 |
|
|||
Numerator - basic and diluted: |
|
|
|
|
|
|
|
|
|
|||
Net loss - basic and diluted |
|
$ |
(285,422 |
) |
|
$ |
(318,758 |
) |
|
$ |
(209,360 |
) |
Net loss attributable to common stockholders - basic and diluted |
|
$ |
(285,422 |
) |
|
$ |
(318,758 |
) |
|
$ |
(209,360 |
) |
Denominator - basic and diluted: |
|
|
|
|
|
|
|
|
|
|||
Weighted-average common shares outstanding - basic and diluted |
|
|
86,625,610 |
|
|
|
85,622,065 |
|
|
|
70,370,519 |
|
The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares, in 000s):
|
|
December 31, |
|
|||||||||
|
|
2025 |
|
|
2024 |
|
|
2023 |
|
|||
Options to purchase common |
|
|
13,128 |
|
|
|
11,688 |
|
|
|
10,685 |
|
Non-vested RSUs |
|
|
2,618 |
|
|
|
1,304 |
|
|
|
309 |
|
ESPP to purchase common stock |
|
|
127 |
|
|
|
70 |
|
|
|
35 |
|
For additional information related to the Company's common stock see Note 14, Common Stock to these consolidated financial statements.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 26, 2026 | Showing above |
| 2024 | Mar 3, 2025 | |
| 2023 | Feb 27, 2024 | |
| 2022 | Feb 28, 2023 | |
| 2020 | Mar 12, 2021 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.